Document is current
Any future updates will be listed below
-
Authors
Barberini, Francesca
Pietroni, Riccardo
Ielpo, Simone
Lucarini, Valeria
Nardozi, Daniela
Melaiu, Ombretta
Benvenuto, Monica
Focaccetti, Chiara https://orcid.org/0000-0002-7334-3966
Palumbo, Camilla
Rossin, Federica https://orcid.org/0000-0002-4313-8347
Fruci, Doriana
Olive, Daniel
Masuelli, Laura
Bei, Roberto
Cifaldi, Loredana https://orcid.org/0000-0001-5014-430X
-
Funding
Funding for this research was provided by:
Ministero dell'Istruzione, dell'Università e della Ricerca (P20223RRASS, P2022XZKBM, P2022LZXNW)
Sapienza Università di Roma (RM12218166C5057A)
- License Information
-
More Information
Article History
Received: 21 January 2025
Revised: 25 July 2025
Accepted: 2 September 2025
First Online: 16 October 2025
Competing interests
: D.O. is a cofounder and shareholder of ImCheck Therapeutics, Alderaan Biotechnology and Emergence Therapeutics and has research funds from ImCheck Therapeutics, Alderaan Biotechnology, Cellectis and Emergence Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: All methods were performed in accordance with the relevant guidelines and regulations. No samples from patients were used in this study. NK cells were isolated from buffy-coats obtained from healthy donors, according to the standard procedure of our institutional blood transfusion center (Bambino Gesù Children’s Hospital, Rome, Italy), who signed a written informed consent, in accordance with rules set by the Institutional Review Board of OPBG (Approval of Ethical Committee No. 1267/2016 prot. No. 348).
